Autopsy report · NCT00426985

Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

“Sponsor (Endo Pharmaceuticals) decision (business reasons)”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 381 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Alkemira SA

Sponsor type

Industry

Conditions

Tendonitis; Bursitis

Interventions

Ketoprofen Topical Patch 20%; Placebo

Participants

381

Sites

1

Countries

United States

Trials that died the same way

• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (75% match in meaning)
• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (74% match in meaning)
• Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
  “Industry sponsor decision” (73% match in meaning)
• Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
  “Strategic decision of Sponsor” (73% match in meaning)
• A Study of PY314 in Subjects With Advanced Solid Tumors
  “Sponsor business decision.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.